SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bowen Yin, Yongqian Chen, Limei Zhang, Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson’s Disease, and Levodopa Efficacy, Molecular Diagnosis & Therapy, 2014, 18, 2, 253

    CrossRef

  2. 2
    Peter A. LeWitt, F. Jacob Huff, Robert A. Hauser, Dan Chen, Dmitri Lissin, Katie Zomorodi, Kenneth C. Cundy, Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease, Movement Disorders, 2014, 29, 1
  3. 3
    P. Martínez-Martín, B. Hernández, J. Ricart, Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes españoles con enfermedad de Parkinson, Neurología, 2014, 29, 3, 153

    CrossRef

  4. 4
    P. Martínez-Martín, B. Hernández, J. Ricart, Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease, Neurología (English Edition), 2014, 29, 3, 153

    CrossRef

  5. 5
    Oscar S. Gershanik, Improving l-dopa therapy: The development of enzyme inhibitors, Movement Disorders, 2014, 29, 14
  6. 6
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  7. 7
    M. Kuoppamäki, M. Vahteristo, J. Ellmén, K. Kieburtz, Pooled analysis of phase III with entacapone in Parkinson's disease, Acta Neurologica Scandinavica, 2014, 130, 4
  8. 8
    Michele A Faulkner, Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease, Expert Opinion on Drug Safety, 2014, 13, 8, 1055

    CrossRef

  9. 9
    Talene A Yacoubian, IPX066: a new intermediate- and extended-release carbidopa–levodopa formulation, Neurodegenerative Disease Management, 2013, 3, 2, 123

    CrossRef

  10. 10
    Thomas Müller, Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease, Clinical Neuropharmacology, 2013, 36, 3, 84

    CrossRef

  11. 11
    Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan H. Fox, Jonathan M. Brotchie, Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque, European Journal of Neuroscience, 2013, 37, 5
  12. 12
    Ronald Pfeiffer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  13. 13
    Ronald F. Pfeiffer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  14. 14
    Sandro Zambito Marsala, Manuela Gioulis, Roberto Ceravolo, Michele Tinazzi, A Systematic Review of Catechol-O-Methyltransferase Inhibitors, Clinical Neuropharmacology, 2012, 35, 4, 185

    CrossRef

  15. 15
    Heinz Reichmann, Murat Emre, Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone, Expert Review of Neurotherapeutics, 2012, 12, 2, 119

    CrossRef

  16. You have free access to this content16
    Spyridon (Spyros) Papapetropoulos, Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials, CNS Neuroscience & Therapeutics, 2012, 18, 5
  17. 17
    Olivier Rascol, Paolo Barone, Madhuri Behari, Murat Emre, Nir Giladi, C. Warren Olanow, Evzen Ruzicka, Francesco Bibbiani, David Squillacote, Anna Patten, Eduardo Tolosa, Perampanel in Parkinson Disease Fluctuations, Clinical Neuropharmacology, 2012, 35, 1, 15

    CrossRef

  18. 18
    Kimmo Ingman, Tarja Naukkarinen, Mikko Vahteristo, Irja Korpela, Mikko Kuoppamäki, Juha Ellmén, The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations, European Journal of Clinical Pharmacology, 2012, 68, 3, 281

    CrossRef

  19. 19
    Thomas Müller, Manfred Gerlach, Moussa B.H. Youdim, Peter Riederer, Neurobiology of Psychiatric Disorders, 2012,

    CrossRef

  20. 20
    Chandler E. Gill, Laura A. Allen, Peter E. Konrad, Thomas L. Davis, Mark J. Bliton, Stuart G. Finder, Michael G. Tramontana, C. Chris Kao, Michael S. Remple, Courtney H. Bradenham, P. David Charles, Deep Brain Stimulation for Early-Stage Parkinson's Disease: An Illustrative Case, Neuromodulation: Technology at the Neural Interface, 2011, 14, 6
  21. 21
    L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang, J.-X. Zhu, Entacapone promotes cAMP-dependent colonic Cl secretion in rats, Neurogastroenterology & Motility, 2011, 23, 7
  22. 22
    Mark F. Lew, Monique Somogyi, Kevin McCague, Mickie Welsh, on behalf of the LCE QoL Study Grou, Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off, International Journal of Neuroscience, 2011, 121, 11, 605

    CrossRef

  23. 23
    H.H. Fernandez, P. Odin, Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease, Current Medical Research and Opinion, 2011, 27, 5, 907

    CrossRef

  24. 24
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  25. 25
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  26. 26
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  27. 27
    Karla Eggert, Örjan Skogar, Khaled Amar, Liisa Luotonen, Mikko Kuoppamäki, Mika Leinonen, Helena Nissinen, Wolfgang Oertel, Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study, Journal of Neural Transmission, 2010, 117, 3, 333

    CrossRef

  28. 28
    Thomas Müller, Entacapone, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 8, 983

    CrossRef

  29. 29
    Martin Wolz, Matthias Löhle, Karl Strecker, Uta Schwanebeck, Christine Schneider, Heinz Reichmann, Xina Grählert, Johannes Schwarz, Alexander Storch, Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial, Journal of Neural Transmission, 2010, 117, 11, 1279

    CrossRef

  30. 30
    Kapil D. Sethi, The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease, The Neurologist, 2010, 16, 2, 76

    CrossRef

  31. 31
    Mark Stacy, The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease, Journal of Neural Transmission, 2010, 117, 7, 837

    CrossRef

  32. 32
    Kristiina Haasio, Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors, 2010,

    CrossRef

  33. 33
    Robert A. Hauser, Michel Panisset, Giovanni Abbruzzese, Linda Mancione, Nalina Dronamraju, Algirdas Kakarieka, Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease, Movement Disorders, 2009, 24, 4
  34. You have free access to this content34
    H. Nissinen, M. Kuoppamäki, M. Leinonen, A. H. Schapira, Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson’s disease: a long-term, retrospective analysis, European Journal of Neurology, 2009, 16, 12
  35. 35
    Lauren C Seeberger, Robert A Hauser, Levodopa/carbidopa/entacapone in Parkinson’s disease, Expert Review of Neurotherapeutics, 2009, 9, 7, 929

    CrossRef

  36. 36
    Ripple Talati, Kurt Reinhart, William Baker, C. Michael White, Craig I. Coleman, Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors, Parkinsonism & Related Disorders, 2009, 15, 7, 500

    CrossRef

  37. 37
    Stewart A. Factor, Current status of symptomatic medical therapy in Parkinson’s disease, Neurotherapeutics, 2008, 5, 2, 164

    CrossRef

  38. 38
    C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso, Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes, Neurobiology of Disease, 2008, 32, 3, 340

    CrossRef

  39. 39
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1, 83

    CrossRef

  40. 40
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1
  41. 41
    David J. Brooks, Mika Leinonen, Mikko Kuoppamäki, Helena Nissinen, Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease, Journal of Neural Transmission, 2008, 115, 6, 843

    CrossRef

  42. 42
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  43. 43
    P. Damier, F. Viallet, M. Ziegler, I. Bourdeix, K. Rerat, Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort, European Journal of Neurology, 2008, 15, 7
  44. 44
    M. Jog, M. Panisset, O. Suchowersky, B. Réhel, R. Schecter, Naturalistic evaluation of entacapone in patients with signs and symptoms ofL-dopa wearing-off*, Current Medical Research and Opinion, 2008, 24, 11, 3207

    CrossRef

  45. 45
    G. Linazasoro, J. Kulisevsky, B. Hernández, Should levodopa dose be reduced when switched to stalevo?, European Journal of Neurology, 2008, 15, 3
  46. 46
    Robert A. Hauser, Lisa M. Shulman, Joel M. Trugman, John W. Roberts, Akihisa Mori, Rocco Ballerini, Neil M. Sussman, Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations, Movement Disorders, 2008, 23, 15
  47. 47
    A. N. Boiko, T. T. Batysheva, N. G. Minaeva, L. A. Babina, T. V. Vdovichenko, E. Yu. Zhuravleva, R. K. Shikhkerimov, E. A. Malykhina, A. A. Khozova, K. A. Zaitsev, E. V. Kostenko, Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial), Neuroscience and Behavioral Physiology, 2008, 38, 9, 933

    CrossRef

  48. 48
    Ariel Gordin, David J. Brooks, Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease, Journal of Neurology, 2007, 254, S4, IV37

    CrossRef

  49. 49
    Günther Deuschl, Antanas Vaitkus, Gabriele-Cornelia Fox, Torsten Roscher, Dieter Schremmer, Ariel Gordin, Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off, Movement Disorders, 2007, 22, 11
  50. 50
    Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease, Movement Disorders, 2007, 22, 1
  51. 51
    F. Grandas, B. Hernández, Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention, European Journal of Neurology, 2007, 14, 3
  52. 52
    Theresa A. Zesiewicz, Robert A. Hauser, MEDICAL TREATMENT OF MOTOR AND NONMOTOR FEATURES OF PARKINSON'S DISEASE, CONTINUUM: Lifelong Learning in Neurology, 2007, 13, 12

    CrossRef

  53. 53
    Lauren B. Elman, David J. Houghton, Gregory F. Wu, Howard I. Hurtig, Clyde E. Markowitz, Leo McCluskey, Palliative Care in Amyotrophic Lateral Sclerosis, Parkinson's Disease, and Multiple Sclerosis, Journal of Palliative Medicine, 2007, 10, 2, 433

    CrossRef

  54. 54
    Yoshikuni Mizuno, Ichiro Kanazawa, Sadako Kuno, Nobuo Yanagisawa, Mitsutoshi Yamamoto, Tomoyoshi Kondo, Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients, Movement Disorders, 2007, 22, 1
  55. 55
    Peter Riederer, Manfred Gerlach, Thomas Müller, Heinz Reichmann, Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, 8, 466

    CrossRef

  56. 56
    Günther Deuschl, Carmen Schade-Brittinger, Paul Krack, Jens Volkmann, Helmut Schäfer, Kai Bötzel, Christine Daniels, Angela Deutschländer, Ulrich Dillmann, Wilhelm Eisner, Doreen Gruber, Wolfgang Hamel, Jan Herzog, Rüdiger Hilker, Stephan Klebe, Manja Kloß, Jan Koy, Martin Krause, Andreas Kupsch, Delia Lorenz, Stefan Lorenzl, H. Maximilian Mehdorn, Jean Richard Moringlane, Wolfgang Oertel, Marcus O. Pinsker, Heinz Reichmann, Alexander Reuß, Gerd-Helge Schneider, Alfons Schnitzler, Ulrich Steude, Volker Sturm, Lars Timmermann, Volker Tronnier, Thomas Trottenberg, Lars Wojtecki, Elisabeth Wolf, Werner Poewe, Jürgen Voges, A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease, New England Journal of Medicine, 2006, 355, 9, 896

    CrossRef

  57. 57
    Kelly E. Lyons, Rajesh Pahwa, Conversion From Sustained Release Carbidopa/Levodopa to Carbidopa/Levodopa/Entacapone (Stalevo) in Parkinson Disease Patients, Clinical Neuropharmacology, 2006, 29, 2, 73

    CrossRef

  58. 58
    Alexei Korchounov, Gregory Bogomazov, Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy, Movement Disorders, 2006, 21, 12
  59. 59
    Anette Schrag, Jonathan M Schott, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, The Lancet Neurology, 2006, 5, 4, 355

    CrossRef

  60. 60
    Johan Samanta, Robert A Hauser, Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease, Aging Health, 2006, 2, 2, 209

    CrossRef

  61. 61
    V. Myllylä, T. Haapaniemi, S. Kaakkola, E. Kinnunen, P. Hartikainen, J. Nuutinen, A. Rissanen, A. M. Kuopio, T. Jolma, O. Satomaa, H. Heikkinen, Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study), Acta Neurologica Scandinavica, 2006, 114, 3
  62. 62
    L. Elmer, S. Schwid, S. Eberly, C. Goetz, S. Fahn, K. Kieburtz, D. Oakes, K. Blindauer, P. Salzman, S. Oren, U.L. Prisco, M. Stern, I. Shoulson, Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms, Journal of the Neurological Sciences, 2006, 248, 1-2, 78

    CrossRef

  63. 63
    Georg Ebersbach, Horst Baas, Ilona Csoti, Martina Müngersdorf, Günther Deuschl, Scales in Parkinson’s disease, Journal of Neurology, 2006, 253, S4, iv32

    CrossRef

  64. 64
    Fabrizio Stocchi, The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations, Expert Opinion on Pharmacotherapy, 2006, 7, 10, 1399

    CrossRef

  65. 65
    Alan Diamond, Joseph Jankovic, Treatment of advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 8, 1181

    CrossRef

  66. 66
    Gunnar Wasner, Günther Deuschl, PAIN, 2006,

    CrossRef

  67. 67
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  68. 68
    Jack J. Chen, Stuart H. Isaacson, <b>The "Wearing Off" Phenomenon in Parkinson's Disease: Current Strategies for Optimizing Dopaminergic Therapy in Long-Term Care</b>, The Consultant Pharmacist, 2005, 20, -1, 1

    CrossRef

  69. 69
    S. Papapetropoulos, A.A. Argyriou, Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients, Parkinsonism & Related Disorders, 2005, 11, 4, 265

    CrossRef

  70. 70
    Leslie J Findley, Andrew Lees, Marjo Apajasalo, Anna Pitkänen, Heidi Turunen, Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off, Current Medical Research and Opinion, 2005, 21, 7, 1005

    CrossRef

  71. 71
    H. Reichmann, J. Boas, D. MacMahon, V. Myllyla, A. Hakala, K. Reinikainen, Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations, Acta Neurologica Scandinavica, 2005, 111, 1
  72. 72
    Anette Schrag, Entacapone in the treatment of Parkinson's disease, The Lancet Neurology, 2005, 4, 6, 366

    CrossRef

  73. 73
    Outi Paija, Kari Laine, Eeva-Riitta Kultalahti, Mika Leinonen, Risto Huupponen, Ariel Gordin, Kari Reinikainen, Entacapone Increases Levodopa Exposure and Reduces Plasma Levodopa Variability When Used With Sinemet CR, Clinical Neuropharmacology, 2005, 28, 3, 115

    CrossRef

  74. 74
    Christopher G. Goetz, Werner Poewe, Olivier Rascol, Cristina Sampaio, Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004, Movement Disorders, 2005, 20, 5
  75. 75
    Alexander Storch, Claudia Trenkwalder, Christian Oehlwein, Juliane Winkelmann, Ulrich Polzer, Hans-Peter Hundemer, Johannes Schwarz, High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias, Parkinsonism & Related Disorders, 2005, 11, 6, 393

    CrossRef

  76. 76
    Spiros Konitsiotis, Novel pharmacological strategies for motor complications in Parkinson’s disease, Expert Opinion on Investigational Drugs, 2005, 14, 4, 377

    CrossRef

  77. 77
    Fabrizio Stocchi, Optimising levodopa therapy for the management of Parkinson’s disease, Journal of Neurology, 2005, 252, S4, iv43

    CrossRef

  78. 78
    Anthony E. Lang, Janis Miyasaki, C. Warren Olanow, A. Jon Stoessl, Oksana Suchowersky, Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease, The Canadian Journal of Neurological Sciences, 2005, 32, 03, 277

    CrossRef

  79. 79
    Spiridon Papapetropoulos, D. C. Mash, Psychotic symptoms in Parkinson’s disease, Journal of Neurology, 2005, 252, 7, 753

    CrossRef

  80. 80
    Katherine L. Widnell, Cynthia Comella, Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations, Movement Disorders, 2005, 20, S11
  81. 81
    &NA;, SYMPOSIUM REPORTER 2005, Journal of the American Medical Directors Association, 2005, 6, Supplement 2, iii,4???16

    CrossRef

  82. 82
    D.J. Brooks, Y. Agid, K. Eggert, H. Widner, K. &Oslash;stergaard, A. Holopainen, Treatment of End-of-Dose Wearing-Off in Parkinson&rsquo;s Disease: Stalevo<sup>&reg;</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>&reg;</sup>/Comtan<sup>&reg;</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment, European Neurology, 2005, 53, 4, 197

    CrossRef

  83. 83
    Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen, Treatment of motor dysfunction in Parkinson's disease: an overview, Clinical Neurology and Neurosurgery, 2005, 107, 4, 269

    CrossRef

  84. 84
    Dee E Silver, Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®), Expert Review of Neurotherapeutics, 2004, 4, 4, 589

    CrossRef

  85. 85
    Thomas M??ller, Birgit Vo, Kerstin Hellwig, Franz Josef Stein, Thorsten Schulte, Horst Przuntek, Treatment Benefit and Daily Drug Costs Associated with Treating Parkinson???s Disease in a Parkinson???s Disease Clinic, CNS Drugs, 2004, 18, 2, 105

    CrossRef

  86. 86
    Michael Schachter, 2004,

    CrossRef

  87. 87
    Oscar Gershanik, Murat Emre, Gudrun Bernhard, Dirk Sauer, Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 6, 963

    CrossRef

  88. 88
    Reina Benabou, Cheryl Waters, Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease, Expert Opinion on Drug Safety, 2003, 2, 3, 263

    CrossRef

  89. 89
    Fabrizio Stocchi, Prevention and treatment of motor fluctuations, Parkinsonism & Related Disorders, 2003, 9, 73

    CrossRef

  90. 90
    Werner Poewe, Psychosis in Parkinson's disease, Movement Disorders, 2003, 18, S6
  91. 91
    J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen, The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease, European Journal of Neurology, 2003, 10, 2
  92. 92
    Wolfgang H. Oertel, Stanley Fahn, Neurological Disorders, 2003,

    CrossRef

  93. 93
    Current Awareness: Pharmacoepidemiology and Drug Safety, Pharmacoepidemiology and Drug Safety, 2002, 11, 7
  94. 94
    Tim Ibbotson, Karen L. Goa, Management of Parkinson??s Disease, Disease Management & Health Outcomes, 2002, 10, 10, 643

    CrossRef

  95. 95
    Fabrizio Stocchi, Managing the critical problems of advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2002, 2, 6, 835

    CrossRef

  96. 96
    Katherine Deane, Sybille Spieker, Carl E Clarke, Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease, The Cochrane Library,
  97. 97
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  98. 98
    Parkinson's Disease, Wiley Handbook of Current and Emerging Drug Therapies,